Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study from Oxford reveals the health service costs for hospital care of people who self-harm, emphasising the need for effective clinical services and prevention initiatives.

Image courtesy of Shutterstock

Self-harm by intentional poisoning or self-injury is a very common reason for presentation to hospital, especially in young people. It is often repeated and carries a significant risk of future suicide. Self-harm was included as a key issue in England’s National Suicide Prevention Strategy for the first time this year. Until now very little information has been available on the costs of hospital care for people who self-harm.

Researchers from the University of Oxford and the London School of Economics have linked information from a register of people presenting to a large general hospital following self-harm to financial records in order to estimate the economic costs of their medical and psychiatric care while in hospital. In a report published in The Lancet Psychiatry they showed that the average cost for each episode of self-harm was £809, with higher costs for adolescents than adults. They estimated that if such costs apply to all self-harm episodes presenting to hospitals in England the overall cost to the NHS amounts to £162 million each year.

 

Read more....

Similar stories

General anaesthesia should be available for dying patients - medical and ethical experts

General Research

General anaesthesia should be more widely available for patients at the end of their lives, according to Oxford experts in ethics and anaesthesia, according to a paper published by Anaesthesia (a journal of the Association of Anaesthetists).

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.